{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:30:45Z","timestamp":1781634645074,"version":"3.54.5"},"reference-count":34,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Dominant optic atrophy (DOA), MIM # 605290, is the most common hereditary optic neuropathy inherited in an autosomal dominant pattern. Clinically, it presents a progressive decrease in vision, central visual field defects, and retinal ganglion cell loss. A biallelic mode of inheritance causes syndromic DOA or Behr phenotype, MIM # 605290. This case report details a family with Biallelic Optic Atrophy 1 (OPA1). The proband is a child with a severe phenotype and two variants in the OPA1 gene. He presented with congenital nystagmus, progressive vision loss, and optic atrophy, as well as progressive ataxia, and was found to have two likely pathogenic variants in his OPA1 gene: c.2287del (p.Ser763Valfs*15) maternally inherited and c.1311A&gt;G (p.lIle437Met) paternally inherited. The first variant is predicted to be pathogenic and likely to cause DOA. In contrast, the second is considered asymptomatic by itself but has been reported in patients with DOA phenotype and is presumed to act as a phenotypic modifier. On follow-up, he developed profound vision impairment, intractable seizures, and metabolic strokes. A literature review of reported biallelic OPA1-related Behr syndrome was performed. Twenty-one cases have been previously reported. All share an early-onset, severe ocular phenotype and systemic features, which seem to be the hallmark of the disease.<\/jats:p>","DOI":"10.3390\/genes13061005","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T04:46:23Z","timestamp":1654145183000},"page":"1005","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Biallelic Optic Atrophy 1 (OPA1) Related Disorder\u2014Case Report and Literature Review"],"prefix":"10.3390","volume":"13","author":[{"given":"Bayan Al","family":"Othman","sequence":"first","affiliation":[{"name":"Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7589-8917","authenticated-orcid":false,"given":"Jia Ern","family":"Ong","sequence":"additional","affiliation":[{"name":"College of Osteopathic Medicine, Des Moines University, Des Moines, IA 50312, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7650-290X","authenticated-orcid":false,"given":"Alina V.","family":"Dumitrescu","sequence":"additional","affiliation":[{"name":"Pediatric Ophthalmology and Strabismus, Inherited Eye Disease, University of Iowa Hospitals and Clinics, Iowa, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1750-1172-7-46","article-title":"Dominant optic atrophy","volume":"7","author":"Lenaers","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.ophtha.2013.04.022","article-title":"Dominant optic atrophy: Novel OPA1 mutations and revised prevalence estimates","volume":"120","author":"Patrick","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.preteyeres.2003.10.003","article-title":"Mitochondrial dysfunction as a cause of optic neuropathies","volume":"23","author":"Carelli","year":"2004","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.bbamcr.2006.04.003","article-title":"Mitochondrial dynamics and disease, OPA1","volume":"1763","author":"Olichon","year":"2006","journal-title":"Biochim. Et Biophys. Acta Mol. Cell Res."},{"key":"ref_5","first-page":"124","article-title":"OPA1: 516 unique variants and 831 patients registered in an updated centralized Variome database","volume":"14","author":"Lenaers","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/brain\/awq007","article-title":"Multi-system neurological disease is common in patients with OPA1 mutations","volume":"133","author":"Man","year":"2010","journal-title":"Brain"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000115062","article-title":"Complicated optic atrophy (Behr\u2019s disease) associated with epilepsy and amino acid imbalance","volume":"18","author":"Monaco","year":"1979","journal-title":"Eur. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/79936","article-title":"Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy","volume":"26","author":"Delettre","year":"2000","journal-title":"Nat. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1086\/324651","article-title":"Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or costeff optic atrophy syndrome): Identification of the OPA3 gene and its founder mutation in Iraqi Jews","volume":"69","author":"Anikster","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1212\/WNL.39.4.595","article-title":"A familial syndrome of infantile optic atrophy, movement disorder, and spastic paraplegia","volume":"2","author":"Costeff","year":"1989","journal-title":"Neurology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ana.410330117","article-title":"3-Methylglutaconic aciduria in \u2018optic atrophy plus\u2019","volume":"33","author":"Costeff","year":"1993","journal-title":"Ann. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1093\/brain\/awu165","article-title":"Pure and syndromic optic atrophy explained by deep intronic OPA1 mutations and an intralocus modifier","volume":"2","author":"Bonifert","year":"2014","journal-title":"Brain"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ophtha.2010.07.029","article-title":"Genetic screening for OPA1 and OPA3 mutations in patients with suspected inherited optic neuropathies","volume":"118","author":"Patrick","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s11011-019-00415-2","article-title":"Metabolic stroke in a patient with bi-allelic OPA1 mutations","volume":"34","author":"Zerem","year":"2019","journal-title":"Metab. Brain Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13023-017-0641-1","article-title":"Not only dominant, not only optic atrophy: Expanding the clinical spectrum associated with OPA1 mutations","volume":"12","author":"Nasca","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Li, Y., Li, J., Jia, X., Xiao, X., Li, S., and Guo, X. (2017). Genetic and clinical analyses of DOA and LHON in 304 chinese patients with suspected childhood-onset hereditary optic neuropathy. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0170090"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/humu.21438","article-title":"LOVD v. 2.0: The next generation in gene variant databases","volume":"32","author":"Fokkema","year":"2011","journal-title":"Hum. Mutat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.scr.2016.09.012","article-title":"Generation of optic atrophy 1 patient-derived induced pluripotent stem cells (iPS-OPA1-BEHR) for disease modeling of complex optic atrophy syndromes (Behr syndrome)","volume":"17","author":"Hauser","year":"2016","journal-title":"Stem. Cell Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1016\/j.bbadis.2018.08.004","article-title":"Deciphering OPA1 mutations pathogenicity by combined analysis of human, mouse and yeast cell models","volume":"1864","author":"Dotto","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1093\/brain\/awu187","article-title":"Reply: Early-onset Behr syndrome due to compound heterozygous mutations in OPA1","volume":"137","author":"Patrick","year":"2014","journal-title":"Brain"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"E692","DOI":"10.1002\/humu.21025","article-title":"Molecular screening of 980 cases of suspected hereditary optic neuropathy with a report on 77 novel OPA1 mutations","volume":"30","author":"Bonneau","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbabio.2009.02.024","article-title":"Retinal ganglion cell neurodegeneration in mitochondrial inherited disorders","volume":"1787","author":"Carelli","year":"2009","journal-title":"Biochim. Et Biophys. Acta Bioenerg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1093\/brain\/awu184","article-title":"Letter to the editor: Early-onset Behr syndrome due to compound heterozygous mutations in OPA1","volume":"137","author":"Bonneau","year":"2014","journal-title":"Brain"},{"key":"ref_24","first-page":"12","article-title":"Visual evoked potentials: Normative values and gender differences","volume":"9","author":"Sharma","year":"2015","journal-title":"J. Clin. Diagnostic Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ymgme.2011.04.018","article-title":"Early-onset severe neuromuscular phenotype associated with compound heterozygosity for OPA1 mutations","volume":"103","author":"Schaaf","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/hmg\/10.13.1359","article-title":"OPA1 mutations in patients with autosomal dominant optic atrophy and evidence for semi-dominant inheritance","volume":"10","author":"Pesch","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3892\/mmr.2016.5209","article-title":"Recessive optic atrophy, sensorimotor neuropathy and cataract associated with novel compound heterozygous mutations in OPA1","volume":"14","author":"Lee","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1093\/brain\/awu234","article-title":"\u2018Behr syndrome\u2019 with OPA1 compound heterozygote mutations","volume":"138","author":"Carelli","year":"2015","journal-title":"Brain A J. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ejpn.2017.04.004","article-title":"Leigh-like neuroimaging features associated with new biallelic mutations in OPA1","volume":"21","author":"Rubegni","year":"2017","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.nbd.2015.08.015","article-title":"OPA1-related disorders: Diversity of clinical expression, modes of inheritance and pathophysiology","volume":"90","author":"Delphine","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.mito.2009.03.001","article-title":"Mitochondrial disorder with OPA1 mutation lacking optic atrophy","volume":"9","author":"Milone","year":"2009","journal-title":"Mitochondrion"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/brain\/awq306","article-title":"Heterozygous OPA1 mutations in Behr syndrome","volume":"134","author":"Marelli","year":"2011","journal-title":"Brain"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1212\/WNL.0000000000003491","article-title":"Dysregulated mitophagy and mitochondrial organization in optic atrophy due to OPA1 mutations","volume":"88","author":"Liao","year":"2017","journal-title":"Neurology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.neuroscience.2016.01.042","article-title":"A randomized, placebo-controlled trial of the benzoquinone idebenone in a mouse model of OPA1-related dominant optic atrophy reveals a limited therapeutic effect on retinal ganglion cell dendropathy and visual function","volume":"319","author":"Smith","year":"2016","journal-title":"Neuroscience"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/6\/1005\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:23:44Z","timestamp":1760138624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/6\/1005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["genes13061005"],"URL":"https:\/\/doi.org\/10.3390\/genes13061005","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]}}}